Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629651 | 0.74 | ASIC3 (0.48) | PIK3CGPIK3CDPIK3CBPIK3C3ADORA2A | |
| SCHEMBL10442596 | 0.73 | HCAR2 (0.46) | PIK3CGPIK3CDPIK3CBPIK3C3ADORA2A | |
| SCHEMBL17203567 | 0.72 | ADORA2A (0.42) | PIK3CGPIK3CDPIK3CBPIK3C3PIK3CA | |
| SCHEMBL20040131 | 0.71 | NOS1 (0.54) | PIK3CGPIK3CDPIK3CBPIK3C3ADORA2A | |
| SCHEMBL17204254 | 0.71 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CBPIK3C3PIK3CA | |
| SCHEMBL14041780 | 0.71 | GAA (0.43) | — | |
| SCHEMBL4146257 | 0.69 | — | — | |
| SCHEMBL17203507 | 0.68 | PIK3CD (0.49) | PIK3CGPIK3CDPIK3CBPIK3C3PIK3CA | |
| SCHEMBL17032982 | 0.68 | SYK (0.39) | PIK3CGPIK3CDPIK3CBPIK3C3PIK3CA | |
| SCHEMBL15859041 | 0.68 | CCR1 (0.54) | ADORA2ANOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306071-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306071-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | PIK3CG 410/4885PIK3CD 366/4885PIK3CB 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.